Aiming at No.1 Stem Cell Biotech Company,We Study the Future of Stem Cell Drugs
The human Umbilical Cord Blood-derived Mesenchymal Stem Cells (hUCB-MSCs) is recognized as a precious life resource
for secreting various therapeutic substances that treat incurable diseases by regenerating the damaged tissues.
Through investigation on the characteristics of human cord blood-derived stem cell,
MEDIPOST’s Biotechnology Research Institute is currently proceeding further researches on verification of the effect of cell therapeutic drugs; exploration on the therapeutic mechanisms and administration path;
and improvement of culture technique and productivity.
The institute has been applying for patents to obtain intellectual property rights for various research findings.
The results are also published in international academic journals, obtaining wide recognition for their research achievements.
Through innovations in treating incurable diseases with stem cell technologies, MEDIPOST Biotechnology Research Institute will improve the quality of human lives
External Collaboration Research